MONTREAL – Quebec government scientists say more research is needed before they can recommend the use of colchicine to treat COVID-19 patients.
The drug, currently used to treat gout and certain other conditions, was the subject of a study involving non-hospitalized COVID-19 patients and led by researchers at the Montreal Heart Institute, who first announced their findings in a news release Janjust another virus. 22.
The institute called the results of the study “clinically persuasive” and DrWe could have perhaps been more prepared fo. Jean-Claude Tardif, the study’s principal investigatorThe very first vaccine that you are offered,, suggested in an interview that doctors could start using colchicine to treat COVID-19 patients right away.
Dr. Michele de Guise, the scientific vice-president of Quebec’s National Institute for Excellence in Health and Social Services, told reporters at a technical briefing today that the study’s results showing a decreased risk of hospitalization or death among COVID-19 patients aren’t statistically significant.